Phase II, prospective, open-label study of a weekly schedule of irinotecan in patients with advanced colorectal cancer.

被引：0
|
作者：
Casinello, J
Dorta, J
Aguiar, J
Pérez-Carrión, J
Castellanos, J
Valladares, J
Sevilla, J
Belón, J
Fernández, J
Casal, J
机构：
[1] H Meixoeiro, Pontevedra, Spain
[2] H del Bierzo, Leon, Spain
[3] H Virgen de las Nieves, Granada, Spain
[4] H Virgen de la Victoria, Malaga, Spain
[5] H Juan Canalejo, La Coruna, Spain
[6] H Xeral Cies, Pontevedra, Spain
[7] H Princesa, Madrid, Spain
[8] H Gran Canarias, Madrid, Spain
[9] Na Sa Candelaria, Tenerife, Spain
[10] H Guadalajara, Tenerife, Spain
来源：
ANNALS OF ONCOLOGY | 2000年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
198P
引用
收藏
页码：46 / 46
页数：1
相关论文
共 50 条
  • [11] Regorafenib in patients with refractory metastatic pancreatic cancer. An open-label phase II study (RESOUND)
    Bozzarelli, S.
    Rimassa, L.
    Giordano, L.
    Sala, S.
    Tronconi, M. C.
    Baretti, M.
    Personeni, N.
    Pressiani, T.
    Santoro, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [12] Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: A phase I-II study
    Santomaggio, A.
    Morelli, M.
    Calista, F.
    Cannita, K.
    Porzio, G.
    Rispoli, A.
    Mancini, M.
    Marchetti, P.
    Ficorella, C.
    Ricevuto, E.
    ANNALS OF ONCOLOGY, 2006, 17 : 78 - 78
  • [13] Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: A phase I-II study
    Santomaggio, A.
    Morelli, M. F.
    Calista, F.
    Guglielmi, F.
    Cannita, K.
    Porzio, G.
    Rispoli, Al
    Mancini, M.
    Martella, F.
    Tudini, M.
    Lanfiuti, Baldi P.
    Marchetti, P.
    Ficorella, C.
    Ricevuto, E.
    ANNALS OF ONCOLOGY, 2006, 17 : XI45 - XI46
  • [14] Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients
    Li, Wenhua
    Xu, Jianming
    Shen, Lin
    Liu, Tianshu
    Guo, Weijian
    Zhang, Wen
    Chen, Zhiyu
    Zhu, Xiaodong
    Li, Jin
    BMC CANCER, 2014, 14
  • [15] Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients
    Wenhua Li
    Jianming Xu
    Lin Shen
    Tianshu Liu
    Weijian Guo
    Wen Zhang
    Zhiyu Chen
    Xiaodong Zhu
    Jin Li
    BMC Cancer, 14
  • [16] Capecitabine and oxaliplatin: A phase II study with a new schedule of administration in elderly patients with advanced colorectal cancer.
    Comandone, A
    Pochettino, P
    Bergnolo, P
    Boglione, A
    Dal Canton, O
    Cutin, SC
    Garetto, F
    Biscardi, M
    Oliva, C
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 291S - 291S
  • [17] Irinotecan/capecitabine with or without bevacizumab in metastatic colorectal cancer: Results of a prospective open-label phase iv trial
    Sprinzl, M.
    Kanzler, S.
    Abdelfatah, M.
    Adami, B.
    Ehscheid, P.
    Flieger, D.
    Goedderz, W.
    Teufel, A.
    Galle, P.
    Moehler, M.
    ANNALS OF ONCOLOGY, 2007, 18 : VII44 - VII45
  • [18] Irinotecan/capecitabine with or without bevacizumab in metastatic colorectal cancer: Results of a prospective open-label phase IV trial
    Moehler, M.
    Sprinzi, M. F.
    Abdelfatah, M.
    Adami, B.
    Ehscheid, P.
    Flieger, D.
    Goedderz, W.
    Majer, C.
    Galle, P. R.
    Kanzler, S.
    ANNALS OF ONCOLOGY, 2007, 18 : 170 - 171
  • [19] Open label phase II study of capecitabine in combination with irinotecan (XEPTO) in patients with metastatic colorectal Cancer (MCRC)
    Raafat, Jahangir
    Sadighi, S.
    Shahrasbi, A. A.
    ANNALS OF ONCOLOGY, 2004, 15 : 87 - 87
  • [20] Open-label, phase II, multicenter trial of ZD1839 ('Iressa') in patients with advanced breast cancer.
    Albain, K
    Elledge, R
    Gradishar, WJ
    Hayes, DF
    Rowinsky, E
    Hudis, C
    Pusztai, L
    Tripathy, D
    Modi, S
    Rubi, S
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S33 - S33
12345